CN111588767A - Grapefruit seed gynecological gel - Google Patents
Grapefruit seed gynecological gel Download PDFInfo
- Publication number
- CN111588767A CN111588767A CN202010624257.XA CN202010624257A CN111588767A CN 111588767 A CN111588767 A CN 111588767A CN 202010624257 A CN202010624257 A CN 202010624257A CN 111588767 A CN111588767 A CN 111588767A
- Authority
- CN
- China
- Prior art keywords
- extract
- grapefruit seed
- parts
- soaking
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses grapefruit seed gynecological gel which comprises 1-4 parts by weight of grapefruit seed extract and an auxiliary matrix, wherein the auxiliary matrix comprises 1-3 parts by weight of beta-glucan, 10.5-3.5 parts by weight of oligopeptide, 0.5-1 part by weight of menthol, 1-4 parts by weight of trehalose and 50-75 parts by weight of water. The grapefruit seed extract disclosed by the invention has good inhibitory activity on escherichia coli, staphylococcus aureus and salmonella, has good inhibitory effect on fungi, can inhibit and kill various gynecological infection bacteria by adding the grapefruit seed extract into a gynecological gel system, plays a role in diminishing inflammation and relieving itching, and has obvious effect on treating various gynecological diseases such as vaginitis and cervicitis.
Description
Technical Field
The invention relates to the technical field of medicinal chemistry, in particular to grapefruit seed gynecological gel.
Background
Female reproductive organs are naturally warm and moist and are easy to breed microorganisms. Normally, the self-heating structure and chemical environment of human body can play a role in protection, so that the disease is prevented. On one hand, the labia majora on both sides of the pudendum is naturally folded to cover the vaginal orifice, so that exogenous microorganisms are difficult to enter; in the vagina, the front wall and the rear wall of the vagina are tightly attached under the action of the pelvic floor muscles, the vaginal orifice is closed, and the external pollution can be prevented to a certain extent. On the other hand, under the influence of estrogen, vaginal epithelial cells are continuously metabolized, proliferated and thickened, and the resistance to pathogens is increased; meanwhile, under the action of the vaginal bacilli, glycogen rich in vaginal epithelial cells can be decomposed into lactic acid to maintain the normal acidic environment of the vagina, so that pathogens suitable for propagation in a weak alkali environment are inhibited. Thus, healthy women usually do not cause inflammation in their vagina, although some bacteria are present. Normally, vaginal bacillus predominates, and few anaerobic bacteria, mycoplasma and candida are present in the vagina, and the flora forms a certain ecological balance. However, when the ecological balance of the vagina is disrupted by a change in human immunity, endocrine hormones, or external factors such as tissue damage and sexual intercourse, the resident flora may cause vaginal infection, and pathogenic microorganisms from the outside may be introduced while being consumed. In addition, with age, childbirth, etc., women gradually loose their vagina and risk of foreign microbial invasion increases. When such gynecological diseases occur, except relying on the autoimmune system, the treatment should be usually combined with medication, such as oral antibiotics, external bacteriostatic drugs, etc. Because the infection is different from the infection of organs in vivo, the disease position is on the body surface, and the curative effect of the external medicine is more direct. The vaginal antibacterial drugs in the prior art can be divided into two categories, wherein one category is the antibacterial drugs taking antibiotics as effective components, and the drugs have quick effect, are easy to have tolerance and have no selectivity on the inhibition of microorganisms, so that the vaginal flora needs to be reconstructed for a long time after the drug is stopped, and the reinfection is easy to occur in the process; the other type of antibacterial drugs take the traditional Chinese medicine composition as an active ingredient, and have the advantages of less skin irritation and no microbial tolerance phenomenon, but have the defects of uncertain curative effect and slow effect of part of drugs. Based on the technical scheme, the invention provides grapefruit seed gynecological gel.
Disclosure of Invention
The invention aims to provide grapefruit seed gynecological gel, and aims to solve the problem of slow effect of gynecological medicines in the prior art.
In order to achieve the above purpose, the invention provides the following technical scheme:
the grapefruit seed gynecological gel comprises 1-4 parts by weight of grapefruit seed extract and an auxiliary matrix, wherein the auxiliary matrix comprises 1-3 parts by weight of beta-glucan, 10.5-3.5 parts by weight of oligopeptide, 0.5-1 part by weight of menthol, 1-4 parts by weight of trehalose and 50-75 parts by weight of water.
Research shows that grapefruit seed (grapefruit seed) contains ascorbic acid, phenolic compounds, naringin, tocopherol and the like, and the components can weaken the functions of cell walls and cell membranes of spoilage microorganisms and pathogenic microorganisms and inhibit the activity of enzymes. It has also been reported that these components can also inhibit cell proliferation mechanisms derived from DNA/RNA, and have bactericidal effects on bacteria, yeast, fungi, and the like, and inhibit the production of toxic conversion products, thereby increasing the freshness and shelf life of food. The grapefruit seed extract has good inhibitory activity on escherichia coli, staphylococcus aureus and salmonella, and has good inhibitory effect on fungi. The grapefruit seed extract is added into the gynecological gel system, so that various gynecological infection bacteria can be inhibited and killed, the effects of diminishing inflammation and relieving itching are achieved, and the effect of treating various gynecological diseases such as vaginitis and cervicitis is obvious.
In some embodiments, the composition further comprises 1-8 parts of moutan bark extract, 3-7 parts of phellodendron bark extract and 2-5 parts of sophora flavescens extract.
In some embodiments, the composition further comprises 1-3 parts of albizzia julibrissin durazzini extract and 3-6 parts of plantain herb extract.
In some of these embodiments, the grapefruit seed extract is prepared by the following process: micronizing grapefruit seed, adding 5-10 times of honey, soaking for 2-3h, air drying, soaking the air-dried grapefruit seed powder in a nano-silver colloid solution, heating to 50-60 deg.C, and ultrasonically extracting for 5-10min to obtain a feed liquid, i.e. grapefruit seed extract, wherein the nano-silver colloid solution has a solubility of 12-15ppm/L, a nano-silver particle diameter of 25-50nm, and an ultrasonic frequency of 20 kHz.
The grapefruit seed powder is soaked in honey, and the dried cortex albiziae powder is soaked in the nano-silver colloid solution, so that the inhibiting effect of the grapefruit seed extract on escherichia coli, staphylococcus aureus and salmonella can be greatly improved.
In some of these embodiments, the moutan bark extract is prepared by: micronizing cortex moutan, soaking in 5-10 times of water for 2-3 hr, heating and reflux extracting for 1.5-3 hr, filtering the extractive solution, concentrating the 1/2 filtrate, drying, subjecting the other part of filtrate to macroporous adsorbent resin column chromatography, washing the column with water, discarding the water washing solution, eluting with 75-90% ethanol, filtering the eluate, concentrating, drying, and mixing the two powders to obtain cortex moutan extract.
In some of these embodiments, the phellodendron extract is prepared by the following method: micronizing cortex Phellodendri leaves, soaking in 5-10 times of water for 2-3 hr, heating and reflux-extracting for 1.5-3 hr, filtering the extractive solution, concentrating the 1/2 filtrate, drying, subjecting the other part of the filtrate to macroporous adsorbent resin column chromatography, washing the column with water, discarding the water washing solution, eluting with 75-90% ethanol, filtering the eluate, concentrating, drying, and mixing the two powders to obtain cortex Phellodendri extract.
In some of these embodiments, the sophora flavescens extract is prepared by the following method: micronizing radix Sophorae Flavescentis, soaking in 5-10 times of water for 2-3 hr, heating and reflux extracting for 1.5-3 hr, filtering the extractive solution, concentrating the 1/2 filtrate, drying, subjecting the other part of filtrate to macroporous adsorbent resin column chromatography, washing the column with water, discarding the water washing solution, eluting with 75-90% ethanol, filtering the eluate, concentrating, drying, and mixing the two powders to obtain radix Sophorae Flavescentis extract.
In some of these embodiments, the albizzia julibrissin durazzini extract is prepared by: micronizing cortex Albizziae, adding 5-10 times of Mel, soaking for 2-3h, air drying, soaking the air dried cortex Albizziae powder in nanometer argentum colloid solution, heating to 50-60 deg.C, ultrasonic extracting for 5-10min to obtain feed liquid, which is cortex Albizziae extract, wherein the nanometer argentum colloid solution has solubility of 12-15ppm/L, nanometer argentum particle diameter of 25-50nm, and ultrasonic frequency of 20 kHz.
In some of these embodiments, the plantain extract is prepared by the following method: micronizing herba plantaginis, adding 5-10 times of Mel, soaking for 2-3h, air drying, soaking the dried cortex Albizziae powder in nanometer argentum glue solution, heating to 50-60 deg.C, and ultrasonic extracting for 5-10min to obtain feed liquid, i.e. herba plantaginis extract, wherein the nanometer argentum glue solution has solubility of 12-15ppm/L, particle diameter of nanometer argentum of 25-50nm, and ultrasonic frequency of 20 kHz.
Compared with the prior art, the grapefruit seed gynecological gel provided by the invention has the following beneficial effects:
the grapefruit seed extract disclosed by the invention has good inhibitory activity on escherichia coli, staphylococcus aureus and salmonella, has good inhibitory effect on fungi, can inhibit and kill various gynecological infection bacteria by adding the grapefruit seed extract into a gynecological gel system, plays a role in diminishing inflammation and relieving itching, and has obvious effect on treating various gynecological diseases such as vaginitis and cervicitis. The cortex moutan extract, the cortex phellodendri extract and the radix sophorae flavescentis extract are further compounded to have the effect of actively killing microorganisms, particularly have good inhibition effect on staphylococcus aureus, escherichia coli and candida albicans, and have quick response and no side effect when being added into gynecological gel. And the cortex albiziae extract and the plantain extract are further compounded into the gynecological gel, so that the gynecological gel has strong inhibiting and killing effects on staphylococcus aureus, escherichia coli, candida albicans and the like, and the effect on treating various gynecological diseases such as vaginitis, cervicitis and the like is accelerated.
The gynecological gel is also suitable for cleaning, bacteriostasis and daily sanitary nursing of the pudendum of women. The using method comprises the following steps: the gynecological gel is used with the help of the booster in a matched manner, the hands are cleaned firstly before the gynecological gel is used, the hip is lifted, the front end protective cap of the booster is removed, then the booster is slowly pushed into the deep vagina, the push rod is pushed, the gel is slowly withdrawn after being pushed into the vagina, and the booster cannot be reused.
Detailed Description
The present invention will be described in detail with reference to specific examples.
Example 1
A grapefruit seed gynecological gel mainly comprises, by weight, 3 parts of grapefruit seed extract, 6 parts of moutan bark extract, 5 parts of phellodendron bark extract, 3 parts of sophora flavescens extract, 2 parts of beta-glucan, 10.8 parts of oligopeptide, 0.6 part of menthol, 3 parts of trehalose and 70 parts of water.
In the above examples, the grapefruit seed extract was prepared by the following method: micronizing grapefruit seed, adding 6 times of honey, soaking for 2h, air drying, soaking the air-dried grapefruit seed powder in a nano-silver colloid solution, heating to 55 ℃, performing ultrasonic extraction for 7min, and obtaining a feed liquid, namely the grapefruit seed extract, wherein the solubility of the nano-silver colloid solution is 14ppm/L, the particle size of nano-silver is 40nm, and the frequency of ultrasonic is 20 kHz.
The moutan bark extract is prepared by the following method: micronizing cortex moutan, soaking in 7 times of water for 3 hr, heating and reflux-extracting for 3 hr, filtering the extractive solution, concentrating the 1/2 filtrate, drying, subjecting the other part of the filtrate to macroporous adsorbent resin column chromatography, washing the column with water, discarding the water washing solution, eluting with 80% ethanol, filtering the eluate, concentrating, drying, and mixing the two powders to obtain cortex moutan extract.
The phellodendron extract is prepared by the following method: micronizing cortex Phellodendri leaves, soaking in 8 times of water for 2 hr, heating under reflux for 1.5 hr, filtering the extractive solution, concentrating the 1/2 filtrate, drying, passing another part of the filtrate through macroporous adsorbent resin column chromatography, washing the column with water, discarding the water washing solution, eluting with 75% ethanol, filtering the eluate, concentrating, drying, and mixing the two powders to obtain cortex Phellodendri extract.
The sophora flavescens extract is prepared by the following method: micronizing radix Sophorae Flavescentis, soaking in 6 times of water for 3 hr, heating under reflux for 2 hr, filtering the extractive solution, concentrating the 1/2 filtrate, drying, subjecting the other part of the filtrate to macroporous adsorbent resin column chromatography, washing the column with water, discarding the water washing solution, eluting with 78% ethanol, filtering the eluate, concentrating, drying, and mixing the two powders to obtain radix Sophorae Flavescentis extract.
Example 2
A grapefruit seed gynecological gel mainly comprises, by weight, 1 part of a moutan bark extract, 7 parts of a phellodendron bark extract, 2 parts of a sophora flavescens extract, 3 parts of beta-glucan, 10.5 parts of oligopeptide, 1 part of menthol, 1 part of trehalose, 3 parts of an albizia bark extract, 3 parts of a plantain herb extract, 4 parts of a grapefruit seed extract and 50 parts of water.
In the above embodiment, the moutan bark extract is prepared by the following method: micronizing cortex moutan, soaking in 7 times of water for 2 hr, heating and reflux-extracting for 2 hr, filtering the extractive solution, concentrating the 1/2 filtrate, drying, subjecting the other part of filtrate to macroporous adsorbent resin column chromatography, washing the column with water, discarding the water washing solution, eluting with 85% ethanol, filtering the eluate, concentrating, drying, and mixing the two powders to obtain cortex moutan extract.
The phellodendron extract is prepared by the following method: micronizing folium Phellodendri, soaking in 9 times of water for 3 hr, heating and reflux-extracting for 2.5 hr, filtering the extractive solution, concentrating the filtrate 1/2, drying, subjecting the other part of the filtrate to macroporous adsorbent resin column chromatography, washing the column with water, discarding the water-washed solution, eluting with 80% ethanol, filtering the eluate, concentrating, drying, and mixing the two powders to obtain cortex Phellodendri extract.
The sophora flavescens extract is prepared by the following method: micronizing radix Sophorae Flavescentis, soaking in 7 times of water for 2 hr, heating under reflux for 2 hr, filtering the extractive solution, concentrating the 1/2 filtrate, drying, subjecting the other part of the filtrate to macroporous adsorbent resin column chromatography, washing the column with water, discarding the water washing solution, eluting with 75-90% ethanol, filtering the eluate, concentrating, drying, and mixing the two powders to obtain radix Sophorae Flavescentis extract.
The albizzia julibrissin durazzini extract is prepared by the following method: micronizing cortex Albizziae, adding 8 times of Mel, soaking for 3h, air drying, soaking the air dried cortex Albizziae powder in nanometer argentum solution, heating to 55 deg.C, and ultrasonically extracting for 8min to obtain feed liquid, namely cortex Albizziae extract, wherein the nanometer argentum solution has solubility of 14ppm/L, nanometer argentum particle diameter of 40nm, and ultrasonic frequency of 20 kHz.
The plantain herb extract is prepared by the following method: micronizing herba plantaginis, adding 6 times of Mel, soaking for 2-3h, air drying, soaking the dried cortex Albizziae powder in nanometer argentum colloid solution, heating to 57 deg.C, and ultrasonically extracting for 7min to obtain feed liquid, i.e. herba plantaginis extract, wherein the nanometer argentum colloid solution has solubility of 14ppm/L, nanometer argentum particle diameter of 25-50nm, and ultrasonic frequency of 20 kHz.
The grapefruit seed extract is prepared by the following method: micronizing grapefruit seed, adding 8 times of honey, soaking for 3h, air drying, soaking the air-dried grapefruit seed powder in a nano-silver colloid solution, heating to 59 ℃, performing ultrasonic extraction for 7min, and obtaining a feed liquid, namely the grapefruit seed extract, wherein the solubility of the nano-silver colloid solution is 13ppm/L, the particle size of nano-silver is 35nm, and the frequency of ultrasonic is 20 kHz.
Example 3
A grapefruit seed gynecological gel mainly comprises, by weight, 8 parts of a moutan bark extract, 3 parts of a phellodendron bark extract, 5 parts of a sophora flavescens extract, 1 part of beta-glucan, 13.5 parts of oligopeptide-13.5 parts, 0.5 part of menthol, 4 parts of trehalose, 1 part of an albizia bark extract, 6 parts of a plantain herb extract, 1 part of a grapefruit seed extract and 75 parts of water.
The preparation methods of the moutan bark extract, the phellodendron bark extract, the sophora flavescens extract, the albizia bark extract, the plantain herb extract and the grapefruit seed extract in example 3 were the same as in example 2.
Example 4
A grapefruit seed gynecological gel mainly comprises, by weight, 5 parts of a moutan bark extract, 4 parts of a phellodendron bark extract, 3 parts of a sophora flavescens extract, 2 parts of beta-glucan, 12 parts of oligopeptide-12 parts, 0.8 part of menthol, 3 parts of trehalose, 2 parts of an albizia bark extract, 5 parts of a plantain herb extract, 3 parts of a grapefruit seed extract and 60 parts of water.
The preparation methods of the moutan bark extract, the phellodendron bark extract, the sophora flavescens extract, the albizia bark extract, the plantain herb extract and the grapefruit seed extract in example 4 were the same as in example 2.
The grapefruit seed gynecological gel prepared in examples 1 to 4 was subjected to clinical trials to test the effects thereof.
Case selection: 300 patients, age 30-35 years, with 100 cases of bacterial vaginitis; 100 cases of mycotic vaginitis; 100 cases of trichomonas vaginitis.
The main symptoms are: leukorrhagia, pruritus vulvae, pain, frequent urination, painful urination or dyspareunia, and congestion of vulvar and vaginal mucosa can be seen during examination. When the object lens examination of vaginal secretion of trichomonas or colpomycosis patients is carried out, trichomonas or fungi can be respectively seen, and the positive examination of bacterial vaginitis BV can be carried out.
The product is used according to the using method of the invention, one booster is used once a day, and one booster is used once a time (namely, 3g of booster) for 7 days continuously.
And (3) judging the curative effect: the method has the following advantages: disappearance of subjective symptoms, vaginal cleanliness (I), vaginal swab culture turning negative or reduced subjective symptoms, vaginal cleanliness (II), and only a few bacteria growing in the vaginal swab culture, no more than 10 at most. And (4) invalidation: the vaginal cleaning degree is not changed, and the vaginal swab culture is not changed.
The results are shown in table 1:
TABLE 1
The features of the embodiments and embodiments described above may be combined with each other without conflict.
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention, and not for limiting the protection scope of the present invention, although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Claims (9)
1. The grapefruit seed gynecological gel is characterized by comprising 1-4 parts by weight of grapefruit seed extract and an auxiliary matrix, wherein the auxiliary matrix comprises 1-3 parts by weight of beta-glucan, 10.5-3.5 parts by weight of oligopeptide, 0.5-1 part by weight of menthol, 1-4 parts by weight of trehalose and 50-75 parts by weight of water.
2. The grapefruit seed gynecological gel according to claim 1, further comprising 1 to 8 parts of a moutan bark extract, 3 to 7 parts of a phellodendron bark extract, and 2 to 5 parts of a sophora flavescens extract.
3. The grapefruit seed gynecological gel according to claim 1, further comprising 1 to 3 parts of an albizzia julibrissin durazz extract and 3 to 6 parts of a plantain herb extract.
4. The grapefruit seed gynecological gel according to claim 1, characterized in that the grapefruit seed extract is prepared by the following method: micronizing grapefruit seed, adding 5-10 times of honey, soaking for 2-3h, air drying, soaking the air-dried grapefruit seed powder in a nano-silver colloid solution, heating to 50-60 deg.C, and ultrasonically extracting for 5-10min to obtain a feed liquid, i.e. grapefruit seed extract, wherein the nano-silver colloid solution has a solubility of 12-15ppm/L, a nano-silver particle diameter of 25-50nm, and an ultrasonic frequency of 20 kHz.
5. The grapefruit seed gynecological gel according to claim 2, wherein the moutan bark extract is prepared by the following method: micronizing cortex moutan, soaking in 5-10 times of water for 2-3 hr, heating and reflux extracting for 1.5-3 hr, filtering the extractive solution, concentrating the 1/2 filtrate, drying, subjecting the other part of filtrate to macroporous adsorbent resin column chromatography, washing the column with water, discarding the water washing solution, eluting with 75-90% ethanol, filtering the eluate, concentrating, drying, and mixing the two powders to obtain cortex moutan extract.
6. The grapefruit seed gynecological gel of claim 2, wherein the phellodendron amurense extract is prepared by the following method: micronizing cortex Phellodendri leaves, soaking in 5-10 times of water for 2-3 hr, heating and reflux-extracting for 1.5-3 hr, filtering the extractive solution, concentrating the 1/2 filtrate, drying, subjecting the other part of the filtrate to macroporous adsorbent resin column chromatography, washing the column with water, discarding the water washing solution, eluting with 75-90% ethanol, filtering the eluate, concentrating, drying, and mixing the two powders to obtain cortex Phellodendri extract.
7. The grapefruit seed gynecological gel according to claim 2, characterized in that the sophora flavescens extract is prepared by the following method: micronizing radix Sophorae Flavescentis, soaking in 5-10 times of water for 2-3 hr, heating and reflux extracting for 1.5-3 hr, filtering the extractive solution, concentrating the 1/2 filtrate, drying, subjecting the other part of filtrate to macroporous adsorbent resin column chromatography, washing the column with water, discarding the water washing solution, eluting with 75-90% ethanol, filtering the eluate, concentrating, drying, and mixing the two powders to obtain radix Sophorae Flavescentis extract.
8. The grapefruit seed gynecological gel according to claim 3, characterized in that the Albizzia julibrissin dura extract is prepared by the following method: micronizing cortex Albizziae, adding 5-10 times of Mel, soaking for 2-3h, air drying, soaking the air dried cortex Albizziae powder in nanometer argentum colloid solution, heating to 50-60 deg.C, ultrasonic extracting for 5-10min to obtain feed liquid, which is cortex Albizziae extract, wherein the nanometer argentum colloid solution has solubility of 12-15ppm/L, nanometer argentum particle diameter of 25-50nm, and ultrasonic frequency of 20 kHz.
9. The grapefruit seed gynecological gel of claim 3, wherein the plantain extract is prepared by the following method: micronizing herba plantaginis, adding 5-10 times of Mel, soaking for 2-3h, air drying, soaking the dried cortex Albizziae powder in nanometer argentum glue solution, heating to 50-60 deg.C, and ultrasonic extracting for 5-10min to obtain feed liquid, i.e. herba plantaginis extract, wherein the nanometer argentum glue solution has solubility of 12-15ppm/L, particle diameter of nanometer argentum of 25-50nm, and ultrasonic frequency of 20 kHz.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010624257.XA CN111588767A (en) | 2020-07-01 | 2020-07-01 | Grapefruit seed gynecological gel |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010624257.XA CN111588767A (en) | 2020-07-01 | 2020-07-01 | Grapefruit seed gynecological gel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111588767A true CN111588767A (en) | 2020-08-28 |
Family
ID=72179706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010624257.XA Pending CN111588767A (en) | 2020-07-01 | 2020-07-01 | Grapefruit seed gynecological gel |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111588767A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114470050A (en) * | 2022-03-21 | 2022-05-13 | 上海相宜本草化妆品股份有限公司 | Traditional Chinese medicine compound composition |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108721441A (en) * | 2018-09-07 | 2018-11-02 | 珂蓝国际（集团）实业有限公司 | Gynecological gel |
| CN109568249A (en) * | 2018-12-17 | 2019-04-05 | 广州植物耀素生物科技有限公司 | A kind of women secret maintenance bacteriostatic gel and its preparation method and application |
| CN111202822A (en) * | 2020-03-27 | 2020-05-29 | 山东川云生物科技有限公司 | Gynecological external antibacterial spray and preparation method thereof |
-
2020
- 2020-07-01 CN CN202010624257.XA patent/CN111588767A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108721441A (en) * | 2018-09-07 | 2018-11-02 | 珂蓝国际（集团）实业有限公司 | Gynecological gel |
| CN109568249A (en) * | 2018-12-17 | 2019-04-05 | 广州植物耀素生物科技有限公司 | A kind of women secret maintenance bacteriostatic gel and its preparation method and application |
| CN111202822A (en) * | 2020-03-27 | 2020-05-29 | 山东川云生物科技有限公司 | Gynecological external antibacterial spray and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 杨磊等: "合欢皮化学成分与药理活性及毒理学研究进展", 《中国中西医结合外科杂志》 * |
| 郭琼妮: "霉菌性阴道炎的护理体会", 《湖南中医杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114470050A (en) * | 2022-03-21 | 2022-05-13 | 上海相宜本草化妆品股份有限公司 | Traditional Chinese medicine compound composition |
| CN114470050B (en) * | 2022-03-21 | 2023-09-05 | 上海相宜本草化妆品股份有限公司 | A Chinese medicinal composition for resisting sensitization, relieving itching and/or repairing skin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111202822A (en) | Gynecological external antibacterial spray and preparation method thereof | |
| KR20120063076A (en) | Antibacterial and antifungal composition and ladies genital area cleanser composition comprising antibacterial and antifungal composition for preventing and treating vaginitis | |
| CN102836367B (en) | Bacteria-resisting, inflammation-diminishing and itching-relieving traditional Chinese medicine composition and preparation method and application thereof | |
| CN103157095B (en) | Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof | |
| CN108853003A (en) | A kind of Nifuratel-Nysfungin soft-capsule type suppository and preparation method thereof | |
| CN104922248A (en) | Antibacterial and anti-inflammatory Chinese herbal compound gel and preparation method thereof | |
| CN111588767A (en) | Grapefruit seed gynecological gel | |
| CN101797269A (en) | Physiological balance liquid for adjusting microecology in vaginas of women | |
| CN108079165A (en) | A kind of gynaecology's washing lotion containing chitosan quaternary ammonium salt and preparation method thereof | |
| CN110585418A (en) | External use disinfection essential oil emulsion for women and production process thereof | |
| CN113274414A (en) | Probiotics preparation for repairing and maintaining vaginal microecological balance | |
| CN100369618C (en) | Application of Chinese medicinal composition in preparation of medicine for treating gynecological inflammation | |
| CN112294886A (en) | Foam type lavender antibacterial lotion and preparation method thereof | |
| CN109602813A (en) | A kind of bacteriostatic gel and preparation method thereof | |
| CN109771595A (en) | A kind of Chinese medicine composition and preparation method thereof for treating gynaecological imflammation | |
| CN109125424A (en) | A kind of plastics and preparation method thereof for preventing and treating mastitis for milk cows | |
| CN115837046A (en) | Ornidazole pessary and preparation method thereof | |
| CN113662998A (en) | A pharmaceutical composition for treating vaginitis and gynecological inflammation, and its preparation method | |
| CN101623368A (en) | Drug for treating gynecological diseases and preparation technology thereof | |
| CN108785383B (en) | Antibacterial gynecological external medicine composition and preparation method and application thereof | |
| CN101007130B (en) | An antibiotic and anti-inflammation traditional Chinese medicine composition and its preparation method | |
| CN102973680B (en) | External linimentum for treating superficial fungal infection and preparation method of external linimentum | |
| CN106581172B (en) | Medicine for preventing and treating mycotic vaginitis, trichomonas vaginitis and senile vaginitis and preparation method thereof | |
| CN112691079A (en) | Foot bacteriostatic care solution containing traditional Chinese medicine extract and preparation method thereof | |
| CN102697686B (en) | Female care solution and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20210519 Address after: 200333 rooms 603, 604, 605, 606, 99 Wuning Road, Putuo District, Shanghai Applicant after: Shanghai Mami weiai Health Technology Co.,Ltd. Address before: 3803, Lanjue International Center, 358 Jincheng Road, Xiaoshan District, Hangzhou City, Zhejiang Province, 311200 Applicant before: Hangzhou weiai e-commerce Co.,Ltd. |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200828 |